|
|
Article: HST Global, Inc. Sets New Standards in the Treatment of Stage IV Breast Cancer!
- Article from:
- Business Wire
- Article date:
- July 30, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HAMPTON, Va. -- Please replace the release dated July 29, 2008 with the following corrected version due to multiple revisions.
The corrected release reads:
HST GLOBAL, INC. SETS NEW STANDARDS IN THE TREATMENT OF STAGE IV BREAST CANCER!
HST Global, Inc., (OTCBB:HSTC) announced today it is meeting with 72% efficacy in pre-clinical treatment of Stage IV cancer in a test of 250 patients. The highlight of the study is in stage IV breast cancer where they have met with 79% efficacy with 58 patients over 2 u years with its drug candidate Salicinium.
Ronald Howell, President & CEO of HST Global, Inc., stated, "We are encouraged by these ...
Related newspaper, magazine, and journal articles:
|
|
Article: HST Global Announces Strategic Alliance for R&D.
Blood Weekly;
October 22, 2009 ;
700+ words
...HST Global, Inc. (OTCBB: HSTC) announced a ... and Medical Food products (see also HST Global, Inc.). "Dr. Forsythe's well ... said Ron Howell, CEO and President of HST Global, Inc. "James will be instrumental ...
|
|